<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11161391</article-id><article-id pub-id-type="pmc">2363737</article-id><article-id pub-id-type="pii">6691610</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1610</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Turner</surname><given-names>S L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gruenewald</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Spry</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gebski</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><collab>on behalf of the Metastron Users Group</collab></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Radiation Oncology, Westmead Hospital, NSW, 2145, Australia</aff><aff id="aff2"><label>2</label>Department of Nuclear Medicine, Westmead Hospital, NSW, 2145, Australia</aff><aff id="aff3"><label>3</label>Department of Radiation Oncology, Charles Gairdner Hospital, Perth, Western Australia 6000</aff><aff id="aff4"><label>4</label>NHMRC Clinical Trials Centre, Sydney University, NSW, 2006, Australia</aff><pub-date pub-type="ppub"><month>02</month><year>2001</year></pub-date><volume>84</volume><issue>3</issue><fpage>297</fpage><lpage>302</lpage><history><date date-type="received"><day>02</day><month>05</month><year>2000</year></date><date date-type="rev-recd"><day>16</day><month>10</month><year>2000</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>93 patients with hormone refractory metastatic prostate cancer were entered on a prospective study to measure reduction in pain and changes in quality of life (QoL) after the administration of 150 MegaBequerel (MBq) Strontium-89 (Sr-89). QoL was assessed using a validated instrument, the Functional Living Index &#x02013; Cancer (FLIC) questionnaire. Pain response was measured using the Radiation Therapy Oncology Group scoring system. Overall there was limited QoL improvement over 3 months following Sr-89. However, in the 53 patients (63&#x00025;) achieving pain responses, QoL did significantly improve within 6 weeks of receiving Sr-89 compared to patients with stable or worsening bone pain, and this was independent of other parameters that might influence QoL outcomes, such as performance status, baseline PSA and extent of skeletal disease (<italic>P</italic> = 0.004). PSA &#x02018;response&#x02019; occurred in 30 patients (37&#x00025;) over 4 months after Sr-89. This did not appear to correlate with clinical improvement. This study supports the presumption that improvement in pain following Sr-89 is accompanied by better QoL. The lack of correlation of PSA response and clinical parameters indicates that in the palliative setting, PSA may not provide a useful surrogate for treatment outcome. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>quality of life</kwd><kwd>strontium-89</kwd><kwd>bone pain</kwd><kwd>prostate cancer</kwd></kwd-group></article-meta></front></article>


